Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.3K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.3K
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

237
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
237
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

135
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
135
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

130
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
130
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

160
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
160
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

414
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
414

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Cancer chemotherapy and pharmacology·2025
Same author

Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.

Clinical and translational science·2025
Same author

Leveraging large language models to compare perspectives on integrating QSP and AI/ML.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug-Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors.

Journal of clinical pharmacology·2025
Same author

A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Sentinel Dosing-Time for a Risk-Based Approach?

Journal of clinical pharmacology·2024
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Automated Pharmacometric Model Development by Leveraging Low-Dimensional Neural ODEs and LASSO Regression.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: Sep 27, 2025

A Quantitative Fitness Analysis Workflow
11:39

A Quantitative Fitness Analysis Workflow

Published on: August 13, 2012

14.6K

Perspectives on training quantitative systems pharmacologists

Tongli Zhang1, Carolyn R Cho2, Peter L Bonate3

  • 1Department of Pharmacology & Systems Physiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

CPT: Pharmacometrics & Systems Pharmacology
|April 7, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Related Experiment Videos

Last Updated: Sep 27, 2025

A Quantitative Fitness Analysis Workflow
11:39

A Quantitative Fitness Analysis Workflow

Published on: August 13, 2012

14.6K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.0K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K